ACM
MDCO

AlphaCrest Capital Management’s Medicines Co MDCO Stock Holding History

AlphaCrest Capital Management’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,800
Closed -$240K – 1453
2019
Q3 		$240K Buy
+4,800
New +$191K 0.01% 1165

Other funds holding MDCO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AlphaCrest Capital Management's MDCO Position: Q4 2019 in Review

AlphaCrest Capital Management sold out of Medicines Co (MDCO) in Q4 2019, closing a stake of 4,800 shares — an estimated $240K sold.

AlphaCrest Capital Management first reported a position in MDCO in Q3 2019 and held it in 1 quarter. The position peaked at $240K in Q3 2019. 284 funds tracked by Wall St. Rank hold MDCO as of Q4 2019.

  • AlphaCrest Capital Management reported no remaining Medicines Co position as of Q4 2019 after selling out during the quarter.
  • AlphaCrest Capital Management sold 4,800 Medicines Co shares in Q4 2019, an estimated $240K.
  • AlphaCrest Capital Management first reported a position in Medicines Co in Q3 2019 and held it in 1 quarter.
  • AlphaCrest Capital Management's Medicines Co position peaked at $240K in Q3 2019.
  • 284 funds tracked by Wall St. Rank held Medicines Co as of Q4 2019.

Based on AlphaCrest Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.